KR20240093832A - 방사성 핵종 복합체의 조합 요법 - Google Patents

방사성 핵종 복합체의 조합 요법 Download PDF

Info

Publication number
KR20240093832A
KR20240093832A KR1020247016801A KR20247016801A KR20240093832A KR 20240093832 A KR20240093832 A KR 20240093832A KR 1020247016801 A KR1020247016801 A KR 1020247016801A KR 20247016801 A KR20247016801 A KR 20247016801A KR 20240093832 A KR20240093832 A KR 20240093832A
Authority
KR
South Korea
Prior art keywords
dota
weeks
administered
subject
mci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016801A
Other languages
English (en)
Korean (ko)
Inventor
파올라 다니엘라 아이모네
다니엘라 키코
마우리치오 에프. 마리아니
에프렌 초어
Original Assignee
노파르티스 아게
어드밴스드 엑셀러레이터 어플리케이션즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 어드밴스드 엑셀러레이터 어플리케이션즈 filed Critical 노파르티스 아게
Publication of KR20240093832A publication Critical patent/KR20240093832A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020247016801A 2021-10-27 2022-10-27 방사성 핵종 복합체의 조합 요법 Pending KR20240093832A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272447P 2021-10-27 2021-10-27
US63/272,447 2021-10-27
PCT/IB2022/060331 WO2023073603A1 (en) 2021-10-27 2022-10-27 Combination therapy of radionuclide complex

Publications (1)

Publication Number Publication Date
KR20240093832A true KR20240093832A (ko) 2024-06-24

Family

ID=84365353

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016801A Pending KR20240093832A (ko) 2021-10-27 2022-10-27 방사성 핵종 복합체의 조합 요법

Country Status (11)

Country Link
US (1) US20250387523A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422701A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539952A (cg-RX-API-DMAC7.html)
KR (1) KR20240093832A (cg-RX-API-DMAC7.html)
CN (1) CN118159304A (cg-RX-API-DMAC7.html)
AU (1) AU2022374887A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234495A1 (cg-RX-API-DMAC7.html)
IL (1) IL312106A (cg-RX-API-DMAC7.html)
MX (1) MX2024004961A (cg-RX-API-DMAC7.html)
TW (1) TW202332473A (cg-RX-API-DMAC7.html)
WO (1) WO2023073603A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129912B1 (en) * 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods

Also Published As

Publication number Publication date
IL312106A (en) 2024-06-01
CA3234495A1 (en) 2023-05-04
JP2024539952A (ja) 2024-10-31
AU2022374887A1 (en) 2024-04-11
CN118159304A (zh) 2024-06-07
MX2024004961A (es) 2024-05-08
US20250387523A1 (en) 2025-12-25
WO2023073603A1 (en) 2023-05-04
EP4422701A1 (en) 2024-09-04
TW202332473A (zh) 2023-08-16

Similar Documents

Publication Publication Date Title
EP3498308B1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
Maini et al. 153Sm-EDTMP for bone pain palliation in skeletal metastases
AU2018366219B2 (en) Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
US8329141B2 (en) Locoregional internal radionuclide ablation of abnormal tissues
RU2095085C1 (ru) Радиофармацевтическая композиция и способы ее получения
RU2160121C2 (ru) Агенты для лучевой терапии, содержащие олово-117m
WO2024176147A1 (en) Methods for treating breast cancer
JPH0448799B2 (cg-RX-API-DMAC7.html)
JP2026505341A (ja) 神経膠芽腫を治療するための方法
US7709613B2 (en) Rhenium-188 and rhenium-186 for treatment of tumors expressing a Na+/I− symporter
EP4422701A1 (en) Combination therapy of radionuclide complex
EP4735056A1 (en) Methods for the diagnosis and/or treatment of neuroendocrine cancers
KR20260014588A (ko) 전립선암의 진단 및/또는 치료 방법
WO2025126151A1 (en) Methods for treating breast cancer
KR20250109190A (ko) 암의 식별 및/또는 치료
Deshayes et al. Anti-MISRII radiolabeled antibodies: new tools for a theranostic approach in ovarian cancer
HK40008701B (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
Maini et al. 153Sm-EDTM for Bone Pain Treatment in Skeletal Metastases
HK40008701A (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
Palmedo Therapy of bone metastases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000